Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01608633
Other study ID # CEU-001
Secondary ID
Status Completed
Phase Phase 2
First received May 27, 2012
Last updated September 3, 2013
Start date March 2012

Study information

Verified date September 2013
Source CEU San Pablo University
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Interventional

Clinical Trial Summary

Pain after dry needling or injection in the muscle is a frequent secondary effect in the treatment of myofascial pain syndrome. In this trial spray and stretch technique is evaluated as a method to reduce this soreness. As well, the characteristics and the different factors that influence in this pain will be described.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date
Est. primary completion date April 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects presenting latent trigger points in the trapezius muscle

Exclusion Criteria:

- Subjects with active trigger points or absence of trigger points.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Spray and stretch
Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.

Locations

Country Name City State
Spain CEU San Pablo University Madrid

Sponsors (1)

Lead Sponsor Collaborator
CEU San Pablo University

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Visual analogue scale 72 hours No
Secondary Pain Pressure pain threshold 48 hours No
Secondary Psychological factors Symptom check list revised. SCL-90-r 72 hours after needling No
See also
  Status Clinical Trial Phase
Completed NCT02158104 - Soreness After Deep Dry Needling of One Latent Myofascial Trigger Point Phase 2/Phase 3